These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 16913519)

  • 1. Provision of bloodborne virus screening in substance misuse.
    Harniman B
    Nurs Times; 2006 Aug 1-7; 102(31):28-30. PubMed ID: 16913519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bloodborne and sexually transmitted infections in drug users in a hospital in Buenos Aires, Argentina.
    Moscatello G; Campello P; Benetucci JA
    Clin Infect Dis; 2003 Dec; 37 Suppl 5():S343-7. PubMed ID: 14648444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seroprevalences and co-infections of HIV, hepatitis C virus and hepatitis B virus in injecting drug users in Quetta, Pakistan.
    Achakzai M; Kassi M; Kasi PM
    Trop Doct; 2007 Jan; 37(1):43-5. PubMed ID: 17326891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia.
    Vicknasingam B; Narayanan S; Navaratnam V
    Drug Alcohol Rev; 2009 Jul; 28(4):447-54. PubMed ID: 19594801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seroprevalence of HBV, HCV and HIV infection among intravenous drug users in Shahr-e-Kord, Islamic Republic of Iran.
    Imani R; Karimi A; Rouzbahani R; Rouzbahani A
    East Mediterr Health J; 2008; 14(5):1136-41. PubMed ID: 19161086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Needle exchange use, sexual risk behaviour, and the prevalence of HIV, hepatitis B virus, and hepatitis C virus infections among Bulgarian injection drug users.
    Vassilev ZP; Hagan H; Lyubenova A; Tomov N; Vasilev G; Krasteva D; Des Jarlais DC
    Int J STD AIDS; 2006 Sep; 17(9):621-6. PubMed ID: 16942654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Audit of bloodborne virus infections in injecting drug users in general practice.
    Peat M; Budd J; Burns SM; Robertson R
    Commun Dis Public Health; 2000 Dec; 3(4):244-6. PubMed ID: 11280250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poor knowledge and low coverage of hepatitis B vaccination among injecting drug users in Sydney.
    Day C; White B; Ross J; Dolan K
    Aust N Z J Public Health; 2003 Oct; 27(5):558. PubMed ID: 14651407
    [No Abstract]   [Full Text] [Related]  

  • 9. Hepatitis C, B, and human immunodeficiency virus infections in illicit drug users in Israel: prevalence and risk factors.
    Loebstein R; Mahagna R; Maor Y; Kurnik D; Elbaz E; Halkin H; Olchovsky D; Ezra D; Almog S
    Isr Med Assoc J; 2008 Nov; 10(11):775-8. PubMed ID: 19070285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving blood-borne viral diagnosis; clinical audit of the uptake of dried blood spot testing offered by a substance misuse service.
    Craine N; Parry J; O'Toole J; D'Arcy S; Lyons M
    J Viral Hepat; 2009 Mar; 16(3):219-22. PubMed ID: 19175879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis services at an injecting drug user outreach clinic.
    Moriarty H; Kemp R; Robinson G
    N Z Med J; 2001 Mar; 114(1128):105-6. PubMed ID: 11346154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus.
    Hourfar MK; Jork C; Schottstedt V; Weber-Schehl M; Brixner V; Busch MP; Geusendam G; Gubbe K; Mahnhardt C; Mayr-Wohlfart U; Pichl L; Roth WK; Schmidt M; Seifried E; Wright DJ;
    Transfusion; 2008 Aug; 48(8):1558-66. PubMed ID: 18466173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bloodborne pathogens. What you need to know--Part II.
    Twitchell KT
    AAOHN J; 2003 Feb; 51(2):89-97; quiz 98-9. PubMed ID: 12655983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of perceptions of hepatitis B and C status. Value of screening for hepatitis C is still debatable.
    Suckling R; Perrett K; McKendrick M
    BMJ; 2000 Feb; 320(7233):513. PubMed ID: 10722302
    [No Abstract]   [Full Text] [Related]  

  • 15. Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia.
    Miller ER; Hellard ME; Bowden S; Bharadwaj M; Aitken CK
    J Infect; 2009 May; 58(5):375-82. PubMed ID: 19328555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990-1995.
    Crofts N; Aitken CK
    Med J Aust; 1997 Jul; 167(1):17-20. PubMed ID: 9236754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV revisited: preventing the spread of blood-borne viruses among injecting drug users.
    Wodak A; Crofts N
    Aust J Public Health; 1994 Sep; 18(3):239-41. PubMed ID: 7841248
    [No Abstract]   [Full Text] [Related]  

  • 18. Incidence of HIV, hepatitis C and hepatitis B viruses among injection drug users in southwestern China: a 3-year follow-up study.
    Ruan Y; Qin G; Yin L; Chen K; Qian HZ; Hao C; Liang S; Zhu J; Xing H; Hong K; Shao Y
    AIDS; 2007 Dec; 21 Suppl 8():S39-46. PubMed ID: 18172390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus seroprevalence: selected health care settings in Texas.
    Melville SK; Heseltine G; Delamater E; Gilani Z; Hendricks K; Suarez L
    Tex Med; 2006 Mar; 102(3):56-61. PubMed ID: 17115588
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug abuse treatment as a strategy to prevent human immunodeficiency virus infection among intravenous drug users. How can we maximize prevention of infection?
    West AP
    Arch Intern Med; 1991 Aug; 151(8):1493-6. PubMed ID: 1651688
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.